Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer

Publication date: Available online 23 November 2017
Source:European Journal of Cancer
Author(s): David Miles, David Cameron, Magalie Hilton, Josep Garcia, Joyce O'Shaughnessy




from Cancer via ola Kala on Inoreader http://ift.tt/2zyJuBO
via IFTTT